Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PepsiCo, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while PepsiCo, Inc. trades at $143.96 (market cap $198.15B). The key difference: PepsiCo, Inc. is far larger — about 44.1× ACADIA Pharmaceuticals Inc.'s market cap, and PepsiCo, Inc. pays a 4.08% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PEP | |
|---|---|---|
Market Cap | $4.49B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $170.44 |
52-Week Low | $20.06 | $133.81 |
Enterprise Value | $3.69B | $240.05B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PepsiCo (PEP) trades at $144.6, up 0.91% on the day, with a bullish technical signal and recent earnings beats. The stock shows strong profitability with a 9.15% net margin and 43.92% ROE, though revenue growth remains modest at 2.2% year-over-year. Recent news highlights price cuts on snacks after consumer pushback on high prices, while the company prepares for Q1 2026 earnings next week.
The outlook is cautiously optimistic with a consensus price target of $161.73 (12% upside). Analyst sentiment leans neutral (63.64% Hold), balancing strong cash flow and brand power against pricing pressures and modest growth. Key risks include execution of North America turnaround and consumer sensitivity to price hikes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
